Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Linagliptin / metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
|
|||
|
|||
Medicine details |
|||
| Medicine name | linagliptin/metformin (Jentadueto®) | ||
| Formulation | 2.5 mg/1000 mg film-coated tablet, 2.5 mg/850 mg film-coated tablet | ||
| Reference number | 2446 | ||
| Indication | Treatment of adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone; and in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products; and, in patients already being treated with the combination of linagliptin and metformin as separate tablets. |
||
| Company | Boehringer Ingelheim Ltd | ||
| BNF chapter | Endocrine system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2114 | ||
| NMG meeting date | 18/06/2014 | ||
| AWMSG meeting date | 16/07/2014 | ||
| Ratification by Welsh Government | 13/08/2014 | ||
| Date of issue | 14/08/2014 | ||
| Date of last review | 23/04/2019 | ||
| Further information This advice incorporates and replaces the existing AWMSG recommendation on linagliptin/metformin (Jentadueto® ) as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus:
|
|||